Accelerating First-in-Human to Proof of Concept with Translational Pharmaceutics® and Enhanced Phase 1 Clinical Study Design
12 October 2026Bringing a new drug candidate from First-in-Human (FIH) studies to proof of concept (PoC) remains one of the most critical stages in drug development. Traditional clinical development models can limit opportunities to generate early formulation and translational insights, potentially delaying key development decisions.
Research conducted across 50 First-in-Human studies performed by Quotient Sciences demonstrates how Translational Pharmaceutics®, an integrated platform combining formulation development, GMP manufacturing, and clinical testing, can help sponsors accelerate development timelines while generating deeper scientific understanding earlier in the development process.
Download the ACCP 2026 poster to learn how Translational Pharmaceutics® and enhanced Phase 1 study designs can accelerate progression from First-in-Human studies to proof of concept.
